Altamira Therapeutics Files 20-F/A Amendment

TL;DR

Altamira Therapeutics (formerly Auris Medical) filed an amended 20-F for 2023, updating its annual disclosures.

AI Summary

Altamira Therapeutics Ltd. filed an amendment (No. 2) to its Form 20-F for the fiscal year ended December 31, 2023. This filing provides updated information and disclosures for the company, which was formerly known as Auris Medical Holding Ltd. The company operates in the pharmaceutical preparations sector.

Why It Matters

This amendment to Altamira Therapeutics' annual report provides updated disclosures for investors and regulatory bodies, reflecting the company's financial and operational status as of December 31, 2023.

Risk Assessment

Risk Level: low — This filing is an amendment to an annual report and does not introduce new material risks or significant financial events.

Key Numbers

• 20231231 — Fiscal Year End (The period for which the annual report is filed.)
• 20240701 — Filing Date (The date the amendment was submitted to the SEC.)

Key Players & Entities

• Altamira Therapeutics Ltd. (company) — Filer of the 20-F/A amendment
• Auris Medical Holding Ltd. (company) — Former name of Altamira Therapeutics Ltd.
• 20240701 (date) — Filing date of the amendment
• 20231231 (date) — Fiscal year end date reported

FAQ

Filing Documents

• ea0208669-20fa2_altamira.htm (20-F/A) — 356KB
• ea020866901ex12-1_altamira.htm (EX-12.1) — 10KB
• ea020866901ex12-2_altamira.htm (EX-12.2) — 10KB
• ea020866901ex13-1_altamira.htm (EX-13.1) — 4KB
• ea020866901ex13-2_altamira.htm (EX-13.2) — 4KB
• ea020866901ex15-3_altamira.htm (EX-15.3) — 3KB
• image_001.jpg (GRAPHIC) — 6KB
• 0001213900-24-057548.txt ( ) — 682KB
• cyto-20231231.xsd (EX-101.SCH) — 3KB
• cyto-20231231_def.xml (EX-101.DEF) — 18KB
• cyto-20231231_lab.xml (EX-101.LAB) — 37KB
• cyto-20231231_pre.xml (EX-101.PRE) — 19KB
• ea0208669-20fa2_altamira_htm.xml (XML) — 8KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No EXPLANATORY NOTE Altamira Therapeutics Ltd. (the "Company") is filing this Amendment No. 2 ("Amendment No. 2") to the Annual Report on Form 20-F for the year ended December 31, 2023 (the "2023 Form 20-F"), as filed with the United States Securities and Exchange Commission (the "SEC") on April 10, 2024 (the "Original Filing Date"), as amended on April 22, 2024, solely to supplement "Item 18: Financial Statements" and "Item 19: Exhibits" of the 2023 Form 20-F with the inclusion of the audited financial statements of Altamira Medica AG (the "Medica Financial Statements"), including the report of BDO AG, an independent registered public accounting firm, relating thereto as required under Rule 3-09 of Regulation S-X. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, this Amendment No. 2 also includes, as Exhibits 12.1, 12.2, 13.1 and 13.2, the certifications of the Principal Executive Officer and Principal Financial Officer of the Company pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. This Amendment No. 2 also includes Exhibit 15.3, which contains the consent of BDO AG, an independent registered public accounting firm, with respect to their report included in the Medica Financial Statements. Except as described above, no changes have been made to the 2023 Form 20-F, and this Amendment No. 2 does not modify, amend or update the financial or other information contained in the 2023 Form 20-F. This Amendment No. 2 does not reflect any events that have occurred on or after the Original Filing Date. Among other things, the Company has not revised forward-looking statements made in the 2023 Form 20-F to reflect events that occurred or facts that became known to the Company after the Original Filing Date. Therefore, this Amendment No. 2 should be read in conjunction wit

Signatures

Signatures The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf. ALTAMIRA THERAPEUTICS LTD. By: /s/ Thomas Meyer Name: Thomas Meyer Title: Chief Executive Officer Date: July 1, 2024 6 Index to Consolidated

Financial Statements

Financial Statements Audited Consolidated Financial Statements — Altamira Medica AG As of December 31, 2023 and for the period of January 1 to December 31, 2023. Independent Auditor's Report (BDO AG, Zurich, Switzerland, PCAOB ID # 5988 ) F-43 Consolidated Statement of Profit or Loss and Other Comprehensive Income / (Loss) F-4 5 Consolidated Statement of Financial Position F-46 Consolidated Statement of Changes in Deficit F-47 Consolidated Statement of Cash Flows F-48 Notes to the consolidated financial statements F-49 F-42 Tel. +41 44 444 35 55 www.bdo.ch zurich@bdo.ch BDO AG Schiffbaustrasse 2 8031 Zrich Independent Auditor's Report Board of Directors Altamira Medica AG Basel Opinion We have audited the consolidated financial statements of Altamira Medica AG and its subsidiary (the Company), which comprise the consolidated statement of financial position as of December 31, 2023, and the related consolidated statements of profit or loss and other comprehensive income/(loss), changes in deficit, and cash flows for the year then ended, and the related notes to the consolidated financial statements. In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023, and the consolidated financial performance and its consolidated cash flows for the year then ended, in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board and Interpretations (collectively "IFRS"). Basis for Opinion We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company, and have fulfilled our other ethical responsibilities, in accordanc

View Full Filing

View this 20-F/A filing on SEC EDGAR